The anti-hyperuricemic effects of compound CC18022 targeting xanthine oxidase
10.16438/j.0513-4870.2021-0270
- VernacularTitle:基于靶点黄嘌呤氧化酶的化合物CC18022抗高尿酸血症作用的研究
- Author:
Xue-chen LI
1
;
Nan JIANG
1
;
Ya-jun YANG
2
;
Zhen-xin YAN
1
;
Lu ZHANG
2
;
Jin-ying TIAN
1
;
Dong-ting CHEN
1
;
Zhi-yan XIAO
2
;
Fei YE
1
Author Information
1. Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
hyperuricemia;
xanthine oxidase;
uric acid;
molecular docking;
CC18022
- From:
Acta Pharmaceutica Sinica
2021;56(6):1621-1626
- CountryChina
- Language:Chinese
-
Abstract:
Hyperuricemia is not only the biochemical basis of gout, but also closely related to the development of metabolic syndrome, cardiovascular diseases, chronic kidney disease, etc. Xanthine oxidase (XOD) is the key catalytic enzyme for uric acid biosynthesis, therefore the vital target for anti-hyperuricemic drugs. In this study, compound CC18022 was designed and synthesized specifically targeting to XOD. Molecular docking analysis indicated a fairly tight binding between CC18022 and XOD. In the in vitro study, CC18022 significantly inhibited XOD activity with a half maximal inhibitory concentration (IC50) value in the order of nmol·L-1, which is relative to the XOD inhibitor febuxostat. By using both acute and chronic hyperuricemic mice model, compound CC18022 was found to have serum uric acid-lowering effect in a dose-dependent manner in vivo. The animal welfare and experimental processes were in accordance with the provisions of the Animal Ethics Committee of the Institute of Materia Medica, Chinese Academy of Medical Sciences. In the acute hyperuricemic mice, CC18022 significantly inhibited serum XOD activity, and also the XOD activity in intestine and liver, which were related to purine absorption and metabolism. Therefore, the novel compound CC18022 exhibited significant inhibition on XOD activity and anti-hyperuricemic effects, making it a favorable candidate for further research.
